Open access
Sep 2026
Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial.
BACKGROUND AND AIMS In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index ≥27 kg/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo. This analysis explored potential mediators of this car...
H. Colhoun, A. Lincoff, D. Ryan et al.
· European Heart Journal · 0 citations